Optimal Management of Refractory Crohn’s Disease: Current Landscape and Future Direction

References

• Ouyang G, Pan G, Liu Q, et al. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. BMC Med. 2020;18(1):388. doi:10.1186/s12916-020-01859-5
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66. doi:10.1038/s41575-020-00360-x
   PubMed Web of Science ®Google Scholar
• Faye AS, Colombel JF. Aging and IBD: a new challenge for clinicians and researchers. Inflamm Bowel Dis. 2022;28(1):126–132. doi:10.1093/ibd/izab039
   PubMed Web of Science ®Google Scholar
• Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254–272 e211. doi:10.1053/j.gastro.2018.08.063
   PubMed Web of Science ®Google Scholar
• Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020;26(1):1–10. doi:10.1093/ibd/izz104
   PubMed Web of Science ®Google Scholar
• Knowles SR, Keefer L, Wilding H, Hewitt C, Graff LA, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm Bowel Dis. 2018;24(5):966–976. doi:10.1093/ibd/izy015
   PubMed Web of Science ®Google Scholar
• Bharadwaj S, Fleshner P, Shen B. Therapeutic armamentarium for stricturing crohn’s disease: medical versus endoscopic versus surgical approaches. Inflamm Bowel Dis. 2015;21(9):2194–2213. doi:10.1097/MIB.0000000000000403
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43(3):317–333. doi:10.1111/apt.13475
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(12):1896–1905. doi:10.1093/ibd/izz059
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–667. doi:10.1016/S0140-6736(08)60304-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. doi:10.1053/j.gastro.2006.11.041
   PubMed Web of Science ®Google Scholar
• Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2011;34(3):306–317. doi:10.1111/j.1365-2036.2011.04717.x
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(3):414–422 e415. doi:10.1016/j.cgh.2013.06.019
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–1582. doi:10.1038/ajg.2010.78
   PubMed Web of Science ®Google Scholar
• Faleck DM, Winters A, Chablaney S, et al. Shorter disease duration is associated with higher rates of response to vedolizumab in patients with crohn’s disease but not ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(12):2497–2505 e2491. doi:10.1016/j.cgh.2018.12.040
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–2030. doi:10.1016/S0140-6736(22)00467-6
   PubMed Web of Science ®Google Scholar
• Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012;18(11):2026–2033. doi:10.1002/ibd.22902
   PubMed Web of Science ®Google Scholar
• Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn’s disease. Inflamm Bowel Dis. 2007;13(9):1093–1099. doi:10.1002/ibd.20177
   PubMed Web of Science ®Google Scholar
• Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose ”escalation” in patients losing response. J Clin Gastroenterol. 2011;45(2):113–118. doi:10.1097/MCG.0b013e3181ebaef9
   PubMed Web of Science ®Google Scholar
• Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s Disease. J Crohns Colitis. 2017;11(5):549–555. doi:10.1093/ecco-jcc/jjw182
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–940. doi:10.1111/apt.13970
   PubMed Web of Science ®Google Scholar
• Faye AS, Lee KE, Hudesman D, Dervieux T. Older adults with inflammatory bowel disease are at higher risk of developing antibodies to infliximab. Inflamm Bowel Dis. 2024. doi:10.1093/ibd/izad305
   PubMed Web of Science ®Google Scholar
• Singh S, Stitt LW, Zou G, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019;49(9):1188–1194. doi:10.1111/apt.15214
   PubMed Web of Science ®Google Scholar
• Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Effectiveness of reinduction and/or dose escalation of ustekinumab in Crohn’s Disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2728–2740 e2721. doi:10.1016/j.cgh.2021.10.002
   PubMed Web of Science ®Google Scholar
• Patel D, Martin S, Luo M, et al. Real-world effectiveness of vedolizumab dose escalation in patients with inflammatory bowel disease: a systematic literature review. Crohns Colitis. 2022;4(3):otac020. doi:10.1093/crocol/otac020
   PubMedGoogle Scholar
• Panaccione R, Long M, Ran Z, et al. S805 Efficacy of upadacitinib dose escalation in a phase 3 long-term extension ulcerative colitis study. Am J Gastroenterol. 2022;117(10S):e574–e575. doi:10.14309/01.ajg.0000859860.18839.f9
   Google Scholar
• Sandborn W, Panes J, Peyrin-Biroulet L, et al. DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: data from the randomised CELEST study. J Crohns Colitis. 2020;14(14):S117–S118. doi:10.1093/ecco-jcc/jjz203.118
   Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(1):105–115 e114. doi:10.1016/j.cgh.2020.09.028
   PubMed Web of Science ®Google Scholar
• Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6). doi:10.3390/ijms20061475
   Web of Science ®Google Scholar
• Pugliese D, Daperno M, Fiorino G, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. Dig Liver Dis. 2019;51(7):972–977. doi:10.1016/j.dld.2019.03.007
   PubMedGoogle Scholar
• Fradkov E, Sheehan J, Cushing K, Higgins PDR. Efficacy of ustekinumab in Crohn’s Disease with and without concurrent autoimmune skin disease. Inflamm Bowel Dis. 2022;28(6):895–904. doi:10.1093/ibd/izab201
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–1560. doi:10.1056/NEJMoa1607017
   PubMed Web of Science ®Google Scholar
• Xie W, Xiao S, Huang H, Zhang Z. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving Anti-TNF therapy: systematic review with meta-analysis. Front Immunol. 2022;13:847160. doi:10.3389/fimmu.2022.847160
   PubMed Web of Science ®Google Scholar
• Toussirot E. The use of janus kinase inhibitors in axial spondyloarthritis: current insights. Pharmaceuticals. 2022;15(3):270. doi:10.3390/ph15030270
   Web of Science ®Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. doi:10.1136/ard-2022-223296
   PubMed Web of Science ®Google Scholar
• Vernero M, Astegiano M, Ribaldone DG. New onset of inflammatory bowel disease in three patients undergoing IL-17A inhibitor secukinumab: a case series. Am J Gastroenterol. 2019;114(1):179–180. doi:10.1038/s41395-018-0422-z
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus Adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–2211.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Chapman C, Colombel JF, et al. S1 risankizumab versus ustekinumab in patients with moderate to severe Crohn’s Disease: results from the phase 3B SEQUENCE Trial. Am J Gastroenterol. 2023;118(12S):S1. doi:10.14309/01.ajg.0000995740.88073.c5
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–1014. doi:10.1016/S2468-1253(21)00312-5
   PubMed Web of Science ®Google Scholar
• Feagan B, Sands BE, Siegel CA, et al. DOP87 the anti-TL1A antibody PRA023 demonstrated proof-of-concept in Crohn’s Disease: phase 2a APOLLO-CD Study Results. J Crohns Colitis. 2023;17(Supplement_1):i162–i164. doi:10.1093/ecco-jcc/jjac190.0127
   Google Scholar
• Sands BE, Peyrin-Biroulet L, Danese S, et al. OP40 PRA023 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active UC: phase 2 ARTEMIS-UC study results. J Crohns Colitis. 2023;17(Supplement_1):i56–i59. doi:10.1093/ecco-jcc/jjac190.0040
   Google Scholar
• Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149(7):1716–1730. doi:10.1053/j.gastro.2015.08.055
   PubMed Web of Science ®Google Scholar
• Reenaers C, Mary JY, Nachury M, et al. Outcomes 7 years after infliximab withdrawal for patients with Crohn’s Disease in sustained remission. Clin Gastroenterol Hepatol. 2018;16(2):234–243 e232. doi:10.1016/j.cgh.2017.09.061
   PubMed Web of Science ®Google Scholar
• Louis E, Resche-Rigon M, Laharie D, et al. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(3):215–227.
   PubMed Web of Science ®Google Scholar
• Raine T, Danese S. Breaking through the therapeutic ceiling: what will it take? Gastroenterology. 2022;162(5):1507–1511. doi:10.1053/j.gastro.2021.09.078
   PubMed Web of Science ®Google Scholar
• McCormack MD, Wahedna NA, Aldulaimi D, Hawker P. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease. World J Clin Cases. 2023;11(12):2621–2630. doi:10.12998/wjcc.v11.i12.2621
   PubMed Web of Science ®Google Scholar
• Alayo QA, Fenster M, Altayar O, et al. Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease. Crohns Colitis. 2022;4(1):otac002. doi:10.1093/crocol/otac002
   PubMedGoogle Scholar
• Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307–320. doi:10.1016/S2468-1253(22)00427-7
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ungaro RC, Sands BE, et al. Vedolizumab, adalimumab, and methotrexate combination therapy in crohn’s disease (EXPLORER). Clin Gastroenterol Hepatol. 2023. doi:10.1016/j.cgh.2023.09.010
   Google Scholar
• Cheong J, Faye A, Shaukat A. Colorectal cancer screening and surveillance in the geriatric population. Curr Gastroenterol Rep. 2023;25(7):141–145.
   PubMedGoogle Scholar
• Lo CH, Lochhead P, Khalili H, et al. Dietary inflammatory potential and risk of crohn’s disease and ulcerative colitis. Gastroenterology. 2020;159(3):873–883 e871. doi:10.1053/j.gastro.2020.05.011
   PubMed Web of Science ®Google Scholar
• Jaber M, Altamimi M, Altamimi A, Cavaliere S, De Filippis F. Mediterranean diet diminishes the effects of Crohn’s disease and improves its parameters: a systematic review. Nutr Health. 2022;2601060221102281. doi:10.1177/02601060221102281
   Google Scholar
• Lewis JD, Sandler RS, Brotherton C, et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s Disease. Gastroenterology. 2021;161(3):837–852 e839. doi:10.1053/j.gastro.2021.05.047
   PubMed Web of Science ®Google Scholar
• Levine A, Wine E, Assa A, et al. Crohn’s Disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440–450 e448. doi:10.1053/j.gastro.2019.04.021
   PubMed Web of Science ®Google Scholar
• Yanai H, Levine A, Hirsch A, et al. The Crohn’s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn’s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022;7(1):49–59. doi:10.1016/S2468-1253(21)00299-5
   PubMed Web of Science ®Google Scholar
• Feng J, Chen Y, Liu Y, et al. Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis. Sci Rep. 2023;13(1):14494. doi:10.1038/s41598-023-41182-6
   PubMed Web of Science ®Google Scholar
• Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study. Microbiome. 2020;8(1):12. doi:10.1186/s40168-020-0792-5
   PubMed Web of Science ®Google Scholar
• Fehily SR, Basnayake C, Wright EK, Kamm MA. Fecal microbiota transplantation therapy in Crohn’s disease: systematic review. J Gastroenterol Hepatol. 2021;36(10):2672–2686. doi:10.1111/jgh.15598
   PubMed Web of Science ®Google Scholar
• Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn’s disease. Aliment Pharmacol Ther. 2008;28(6):724–733. doi:10.1111/j.1365-2036.2008.03796.x
   PubMed Web of Science ®Google Scholar
• Fernández-Banares F, Cabré E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr. 1995;19(5):356–364. doi:10.1177/0148607195019005356
   PubMed Web of Science ®Google Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology. 1995;108(4):1056–1067. doi:10.1016/0016-5085(95)90203-1
   PubMed Web of Science ®Google Scholar
• Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;4(4):Cd000542. doi:10.1002/14651858.CD000542.pub3
   PubMed Web of Science ®Google Scholar
• Breton J, Kastl A, Conrad MA, Baldassano RN. Positioning biologic therapies in the management of pediatric inflammatory bowel disease. Gastroenterol Hepatol. 2020;16(8):400–414.
   Google Scholar
• Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146(2):383–391. doi:10.1053/j.gastro.2013.10.027
   PubMed Web of Science ®Google Scholar
• Kang B, Choe YH. Early biologic treatment in pediatric Crohn’s Disease: catching the therapeutic window of opportunity in early disease by treat-to-target. Pediatr Gastroenterol Hepatol Nutr. 2018;21(1):1–11. doi:10.5223/pghn.2018.21.1.1
   PubMedGoogle Scholar
• Ouahed J, Spencer E, Kotlarz D, et al. Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflamm Bowel Dis. 2020;26(6):820–842. doi:10.1093/ibd/izz259
   PubMedGoogle Scholar
• Alós R, Hinojosa J. Timing of surgery in Crohn’s disease: a key issue in the management. World J Gastroenterol. 2008;14(36):5532–5539. doi:10.3748/wjg.14.5532
   PubMed Web of Science ®Google Scholar
• Stevens TW, Haasnoot ML, D’Haens GR, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020;5(10):900–907. doi:10.1016/S2468-1253(20)30117-5
   PubMed Web of Science ®Google Scholar
• Agrawal M, Ebert AC, Poulsen G, et al. Early ileocecal resection for crohn’s disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: a population-based cohort study. Gastroenterology. 2023;165(4):976–985 e973. doi:10.1053/j.gastro.2023.05.051
   PubMed Web of Science ®Google Scholar
• Fernandez C, Gajic Z, Esen E, et al. Preoperative risk factors for adverse events in adults undergoing bowel resection for inflammatory bowel disease: 15-year assessment of the American college of surgeons national surgical quality improvement program. Am J Gastroenterol. 2023;118(12):2230–2241. doi:10.14309/ajg.0000000000002395
   PubMed Web of Science ®Google Scholar
• Rutgeerts P. Review article: treatment of perianal fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2004;20(Suppl 4):106–110. doi:10.1111/j.1365-2036.2004.02060.x
   PubMedGoogle Scholar
• Lansdorp CA, Gecse KB, Buskens CJ, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease. Aliment Pharmacol Ther. 2021;53(5):587–597.
   PubMed Web of Science ®Google Scholar
• Feitosa MR, Parra RS, Machado VF, et al. Adjunctive hyperbaric oxygen therapy in refractory Crohn’s Disease: an observational study. Gastroenterol Res Pract. 2021;2021:6628142. doi:10.1155/2021/6628142
   PubMed Web of Science ®Google Scholar
• Cao Y, Su Q, Zhang B, Shen F, Li S. Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther. 2021;12(1):32. doi:10.1186/s13287-020-02095-7
   PubMed Web of Science ®Google Scholar
• Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–1290. doi:10.1016/S0140-6736(16)31203-X
   PubMed Web of Science ®Google Scholar
• Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s Disease: surgical treatment. J Crohns Colitis. 2020;14(2):155–168. doi:10.1093/ecco-jcc/jjz187
   PubMed Web of Science ®Google Scholar
• Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2022;57(7):1055–1062. doi:10.1038/s41409-022-01702-w
   PubMed Web of Science ®Google Scholar
• Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn’s disease after allogeneic marrow transplantation. Gastroenterology. 1998;114(3):433–440. doi:10.1016/S0016-5085(98)70525-6
   PubMed Web of Science ®Google Scholar
• Wang R, Yao Q, Chen W, et al. Stem cell therapy for Crohn’s disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther. 2021;12(1):463. doi:10.1186/s13287-021-02533-0
   PubMed Web of Science ®Google Scholar
• Guisado D, Talware S, Singh S, et al. Reprogramming of the intestinal immune cell compartment defines the response to autologous stem cell transplantation in Crohn’s Disease. Inflamm Bowel Dis. 2023;29(Supplement_1):S51–S52. doi:10.1093/ibd/izac247.101
   PubMedGoogle Scholar
• Wrighton KH. Malassezia restricta plays CARDs in the gut. Nat Rev Microbiol. 2019;17(5):266–267. doi:10.1038/s41579-019-0188-3
   PubMed Web of Science ®Google Scholar
• Fornaro R, Actis GC, Caviglia GP, Pitoni D, Ribaldone DG. Inflammatory bowel disease: role of vagus nerve stimulation. J Clin Med. 2022;11(19):5690. doi:10.3390/jcm11195690
   PubMed Web of Science ®Google Scholar